Back HIV/AIDS

HIV / AIDS

WHO Recommends Continued Antiretroviral Treatment for HIV+ Women after Delivery

The World Health Organization (WHO) this month published new guidance recommending that women with HIV who receive combination antiretroviral therapy (ART) during pregnancy for prevention of mother-to-child transmission should remain on ART on an ongoing basis, regardless of CD4 T-cell count.alt

CROI 2012: HIV+ People with CD4 Counts Above 500 Match Life Expectancy of General Population

People with HIV who respond well to antiretroviral therapy (ART) and achieve undetectable viral load and a CD4 T-cell count above 500 cells/mm3 can have a mortality rate similar to that of HIV negative people, but this is not the case for those with 350-500 cells/mm3, according to a study presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle.alt

CROI 2012: Switching to Tenofovir Increases Bone Turnover, Raltegravir Can Improve Bone Density

HIV positive people who substituted tenofovir (Viread) for zidovudine (AZT; Retrovir) in their antiretroviral regimen showed elevated levels of biomarkers associated with bone turnover and decreased bone mineral density (BMD), researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle. A related study found that switching from tenofovir to raltegravir (Isentress) led to increases in bone density.alt

Research Offers Clues to Modest Protection in Thai HIV Vaccine Trial

Researchers have learned more about how an experimental vaccine provides partial protection against HIV infection, according to a report in the April 5, 2012, issue of the New England Journal of Medicine.alt

CROI 2012: Crofelemer Reduces Diarrhea in People with HIV; FDA Grants Priority Review

A plant compound known as crofelemer significantly decreased the frequency of secretory diarrhea in HIV positive patients, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle. The U.S. Food and Drug Administration (FDA) has given crofelemer priority review status and is expected to take action by early June.alt

Zoledronate Protects HIV Positive Men against Bone Loss for at Least 5 Years

The effects of 2 annual doses of zoledronate persist for at least 5 years in HIV positive men on antiretroviral therapy (ART), according to a New Zealand study published in the March 14, 2012, advance online edition of the Journal of Clinical Endocrinology & Metabolism.alt

Female Condom a Cost-Effective Way to Prevent HIV Infection

A female condom distribution and education program in Washington, DC, prevented an estimated 23 new HIV infections and resulted in a substantial net cost savings, according to a retrospective study published in the March 21, 2012, online edition of AIDS and Behavior. Researchers calculated that every dollar spent on the program could potentially return about $20 in cost savings.alt